Updates are available Correction dated 2025-10-31
Click to view Correction: https://doi.org/10.1007/s00330-025-12045-7
-
Authors
Öcal, Osman https://orcid.org/0000-0001-5234-1921
Zech, Christoph Johannes
Bali, Maria Antonietta
Pasquier, David
Mottaghy, Felix
Einspieler, Ingo
Kartalis, Nikolaos
Bargellini, Irene
Iezzi, Roberto
Denecke, Timm
Kunz, Wolfgang Gerhard
Gebauer, Bernhard
Wege, Henning
Cannella, Roberto
Oprea-Lager, Daniela Elena
Vogel, Arndt
Sangro, Bruno
Seidensticker, Max
,
De Felice, Francesca
Pisoni, Serena
Hemmatazad, Hossein
Schütte, Kerstin
Verhoeff, Joost
Peynircioglu, Bora
Guida, Cesare
Dewulf, Maxime
Deroose, Christophe
Dionisi, Valeria
Ramage, John
Venerito, Mario
Burgmans, Mark
de la Pinta, Carolina
Roach, Huw
Aslan, Serdar
Cappio, Stefano
Stroszczynski, Christian
Fehrenbach, Uli
Rimassa, Lorenza
Luerken, Lukas
- License Information
-
More Information
Article History
Received: 12 January 2025
Revised: 6 April 2025
Accepted: 22 April 2025
First Online: 23 May 2025
Change Date: 3 October 2025
Change Type: Update
Change Details: The original online version of this article was revised: In the original article affiliation of study group member Lorenza Rimassa’s affiliation was incorrectly given as IRCCS Humanitas Research Hospital, Roma, Italy. The correct affiliation is Humanitas Cancer Center, IRCCS Humanitas Research Hospital, Rozzano (Milan), Italy. Lorenza Rimassa is also affiliated with Department of Biomedical Sciences, Humanitas University, Pieve Emanuele (Milan), Italy which was left out in the original article.
Change Details: Furthermore, the following Conflict of interest statement was missing in the original article: LR has received consulting fees from AbbVie, AstraZeneca, Basilea, Bayer, BMS, Elevar Therapeutics, Exelixis, Genenta, Hengrui, Incyte, Ipsen, Jazz Pharmaceuticals, MSD, Nerviano Medical Sciences, Roche, Servier, Taiho Oncology, Zymeworks; lecture fees from AstraZeneca, Bayer, BMS, Eisai, Guerbet, Incyte, Ipsen, Roche, Servier; travel expenses from AstraZeneca, Servier; and institutional research funding from AbbVie, AstraZeneca, BeiGene, Exelixis, Fibrogen, Incyte, Ipsen, Jazz Pharmaceuticals, MSD, Nerviano Medical Sciences, Roche, Servier, Taiho Oncology, TransThera Sciences, Zymeworks.
Change Date: 31 October 2025
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s00330-025-12045-7
Compliance with ethical standards
:
: The scientific guarantor of this publication is Osman Öcal.
: The authors of this manuscript declare relationships with the following companies: R.C.: Support for attending meetings from Bracco and Bayer; research collaboration with Siemens Healthineers; co-funding by the European Union—FESR or FSE, PON Research and Innovation 2014-2020—DM 1062/2021. O.Ö. is a Junior Deputy Editor for European Radiology. N.K. is a member of the Scientific Editorial Board of European Radiology (section: Magnetic Resonance). As such, they did not participate in the selection or review processes for this article.
: No complex statistical methods were necessary for this paper.
: Informed consent was not required due to the nature of the study.
: Institutional Review Board approval was not required due to the nature of the study.
: Not applicable.
:
